China’s Diabetes Cure: America’s Last Hope?
One in four American diabetes patients cannot afford insulin, while China’s low-cost diabetes therapies are reportedly being barred from the U.S. market.
Viewed on website
Eli Lilly, Novo Nordisk, and Sanofi have used patents and distribution channels to monopolize the U.S. insulin market, leading to prices over 10 times higher than in China. With Chin…
Keep reading with a 7-day free trial
Subscribe to China Academy Newsletter to keep reading this post and get 7 days of free access to the full post archives.